Alopecia pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(29 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Alopecia}}
{{Alopecia}}


{{CMG}}; {{AE}} [[Jose]]
{{CMG}}; {{AE}} {{Jose}}


==Overview==
==Overview==
Since [[alopecia]] ha many different causes, the pathophysiologic mechanism for its development varies according to the cause.
Since [[alopecia]] has many different causes, the pathophysiologic mechanism for its development varies widely according to the cause. [[Alopecia areata]], for example, is related with [[CD8+]] [[T-cell]] [[autoimmunity]], while [[androgenetic alopecia]] is related with androgen hormones effects' on the hair follicle which leads to its miniaturization and hair loss. [[Tinea capitis]] on the other hand is an infectious disease that can damage the hair follicle and lead to definitive hair loss.


==Pathophysiology==
==Pathophysiology==
The most common causes for [[alopecia]] and its pathophysiology mechanism are briefly discussed below:
===Alopecia Areata===
===Alopecia Areata===
[[File:Alopecia_areata_12.jpeg|200px|thumb|left|Alopecia areata - from atlasdermatologico.com.br]]
* The exact pathogenesis of [[alopecia areata]] is not fully understood.  
* The exact pathogenesis of [[alopecia areata]] is not fully understood.  
* It has been theorized that [[T-cell-mediated autoimmunity]] must be involved in its development.  
* It has been theorized that [[T-cell-mediated autoimmunity]] must be involved in its development.  
* The [[hair follicle]] typically has low levels of [[major histocompatibility complex expression]], which provides protection from the immune system. It is believed that in [[alopecia Areata]] that protection is lost, resulting in a [[CD8+]] [[T lymphocyte]] attack to the bulb of the hair, generating an [[inflammatory infiltrate]] in the [[peribulbar[[ region of the [[hair follicle]].<ref name="pmid14582671">{{cite journal| author=Paus R, Ito N, Takigawa M, Ito T| title=The hair follicle and immune privilege. | journal=J Investig Dermatol Symp Proc | year= 2003 | volume= 8 | issue= 2 | pages= 188-94 | pmid=14582671 | doi=10.1046/j.1087-0024.2003.00807.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14582671  }} </ref><ref name="pmid24326544">{{cite journal| author=Paus R, Bertolini M| title=The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. | journal=J Investig Dermatol Symp Proc | year= 2013 | volume= 16 | issue= 1 | pages= S25-7 | pmid=24326544 | doi=10.1038/jidsymp.2013.7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24326544  }} </ref>
* The [[hair follicle]] typically has low levels of [[major histocompatibility complex expression]], which provides protection from the immune system. It is believed that in [[alopecia Areata]] that protection is lost, resulting in a [[CD8+]] [[T lymphocyte]] attack to the bulb of the hair, generating an [[inflammatory infiltrate]] in the [[peribulbar]] region of the [[hair follicle]].<ref name="pmid14582671">{{cite journal| author=Paus R, Ito N, Takigawa M, Ito T| title=The hair follicle and immune privilege. | journal=J Investig Dermatol Symp Proc | year= 2003 | volume= 8 | issue= 2 | pages= 188-94 | pmid=14582671 | doi=10.1046/j.1087-0024.2003.00807.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14582671  }} </ref><ref name="pmid24326544">{{cite journal| author=Paus R, Bertolini M| title=The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. | journal=J Investig Dermatol Symp Proc | year= 2013 | volume= 16 | issue= 1 | pages= S25-7 | pmid=24326544 | doi=10.1038/jidsymp.2013.7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24326544  }} </ref>
*Genes involved in the pathogenesis of [[alopecia areata]] include [[MCHR2]] and [[MCHR2-AS1]] which are related to the [[MHC]] pathway ([[melanin concentrating hormone]]).<ref name="pmid27306922">{{cite journal| author=Fischer J, Degenhardt F, Hofmann A, Redler S, Basmanav FB, Heilmann-Heimbach S | display-authors=etal| title=Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. | journal=Exp Dermatol | year= 2017 | volume= 26 | issue= 6 | pages= 536-541 | pmid=27306922 | doi=10.1111/exd.13123 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27306922  }} </ref>
*Genes involved in the pathogenesis of [[alopecia areata]] include [[MCHR2]] and [[MCHR2-AS1]] which are related to the [[MHC]] pathway ([[melanin concentrating hormone]]).<ref name="pmid27306922">{{cite journal| author=Fischer J, Degenhardt F, Hofmann A, Redler S, Basmanav FB, Heilmann-Heimbach S | display-authors=etal| title=Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. | journal=Exp Dermatol | year= 2017 | volume= 26 | issue= 6 | pages= 536-541 | pmid=27306922 | doi=10.1111/exd.13123 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27306922  }} </ref>
* There is an association of [[alopecia Areata]] with other autoimmune diseases such as [[vitiligo]], [[autoimmune thyroid disease]], [[celiac disease]], [[systemic erythematous]], [[chronic atrophic gastritis]] which further reinforces its relationship with autoimmunity.<ref name="pmid28717940">{{cite journal| author=Trüeb RM, Dias MFRG| title=Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. | journal=Clin Rev Allergy Immunol | year= 2018 | volume= 54 | issue= 1 | pages= 68-87 | pmid=28717940 | doi=10.1007/s12016-017-8620-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28717940  }} </ref>
* There is an association of [[alopecia Areata]] with other autoimmune diseases such as [[vitiligo]], [[autoimmune thyroid disease]], [[celiac disease]], [[systemic erythematous]], [[chronic atrophic gastritis]] which further reinforces its relationship with autoimmunity.<ref name="pmid28717940">{{cite journal| author=Trüeb RM, Dias MFRG| title=Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. | journal=Clin Rev Allergy Immunol | year= 2018 | volume= 54 | issue= 1 | pages= 68-87 | pmid=28717940 | doi=10.1007/s12016-017-8620-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28717940  }} </ref>
<br>


===Telogen effluvium==  
===Telogen effluvium===
 
* [[Telogen effluvium]] is not a disease per se, but it is a common cause of hair loss due to a triggering event that increases the number of hair follicles that are in the catagen or telogen phase (shedding and resting phase) of the hair development cycle.
*In telogen effluvium, the hair loss may influenced by hormones or stress, or other unknown factors. <ref name="pmid30511001">Yu L, Lu Z (2018) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=30511001 Linear alopecia areata.] ''JAAD Case Rep'' 4 (10):1072-1073. [http://dx.doi.org/10.1016/j.jdcr.2018.08.015 DOI:10.1016/j.jdcr.2018.08.015] PMID: [https://pubmed.gov/30511001 30511001]</ref> The dermatophyte infection is responsible for hair loss in tinea capitis. In anagen effluvium, the shedding of hair is under the effect of chemotherapeutic agents. In alopecia mucinosa, the infiltration of the scalp with abnormal lymphocytes is the cause. <ref name="pmid30501016">{{cite journal| author=Davey L, Clarke V, Jenkinson E| title=Living with alopecia areata: an online qualitative survey study. | journal=Br J Dermatol | year= 2019 | volume= 180 | issue= 6 | pages= 1377-1389 | pmid=30501016 | doi=10.1111/bjd.17463 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30501016 }} </ref>
* It is of non-scarring type.
 
* There are many different events that can act as triggers for this condition, such as [[febrile diseases]] ([[malaria]], [[HIV]], [[tuberculosis]]), [[drugs]] ([[oral contraceptives]], [[anticonvulsants]], [[beta blockers]], [[captopril]] [[antithyroid drugs]] and [[hypolipidemic drugs]]), [[thyroid diseases]], organ dysfunction, nutritional ([[iron]] or [[zinc]] deficiency) or local factors such as hair dye.<ref name="pmid26500992">{{cite journal| author=Malkud S| title=Telogen Effluvium: A Review. | journal=J Clin Diagn Res | year= 2015 | volume= 9 | issue= 9 | pages= WE01-3 | pmid=26500992 | doi=10.7860/JCDR/2015/15219.6492 | pmc=4606321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26500992 }} </ref>
==Pathogenesis==
* Telogen hairs are usually at least at 25% for the diagnosis of telogen effluvium to be made.<ref name="pmid28613598">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=28613598 | doi= | pmc= | url= }} </ref>
Pathogenesis is the mechanism by which a certain factor causes disease (''pathos'' = disease, ''genesis'' = development). The term can also be used to describe the development of the disease, whether it is acute, chronic, or recurrent. It can also be used to describe whether the disease causes inflammation, malignancy, necrosis etc.
 
==== Template Sentences ====
IF the pathogenesis of the disease is unclear:
 
*It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
IF the disease is infectious…
*…and the route of transmission is known:
**[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
**Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
IF the disease has a known genetic component:
*[Disease name] is transmitted in [mode of genetic transmission] pattern.
*Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
IF certain pathology findings are characteristic of the disease:
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
 
==Genetics==
*Some diseases are genetic, and have particular inheritance patterns, and express different phenotypes.
*The effect that genetics may have on the pathophysiology of a disease can be described in this section.


==== Template sentences ====
===Traumatic alopecia===
*[Disease name] is transmitted in [mode of genetic transmission] pattern.
* Usually seen on children that pull their hair, the same mechanism as [[traction alopecia]].
*Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
* May be associated with [[trichotillomania]] - a psychiatric condition in which the patient repeatedly pulls their hair.<ref name="pmid30844205">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30844205 | doi= | pmc= | url= }} </ref>


==Associated Conditions==
===Androgenetic alopecia===
*Conditions associated with the disease can be detailed in this section.
[[File:Alopecia.jpg|200px|thumb|left|Androgenetic alopecia - from atlasdermatologico.com.br]]
* In [[androgenetic alopecia]] there is marked miniaturization of the hair follicle and disruption of the hair cycle.
* It is thought that in [[androgenetic alopecia]] the hair loss is the result of the shortening of the anagen phases of hair development and enlongation of the telogen phase that gradually takes place until the hair eventually doesn't even leave the skin surface.<ref name="pmid14585162">{{cite journal| author=Ellis JA, Sinclair R, Harrap SB| title=Androgenetic alopecia: pathogenesis and potential for therapy. | journal=Expert Rev Mol Med | year= 2002 | volume= 4 | issue= 22 | pages= 1-11 | pmid=14585162 | doi=10.1017/S1462399402005112 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14585162  }} </ref>
* The is also an increase in the period from the hair shedding to its regrowth.<ref name="pmid14585162">{{cite journal| author=Ellis JA, Sinclair R, Harrap SB| title=Androgenetic alopecia: pathogenesis and potential for therapy. | journal=Expert Rev Mol Med | year= 2002 | volume= 4 | issue= 22 | pages= 1-11 | pmid=14585162 | doi=10.1017/S1462399402005112 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14585162  }} </ref>
* The miniaturization affects the hair follicle globally, including the dermal papilla which is essential for its maintenance.<ref name="pmid14585162">{{cite journal| author=Ellis JA, Sinclair R, Harrap SB| title=Androgenetic alopecia: pathogenesis and potential for therapy. | journal=Expert Rev Mol Med | year= 2002 | volume= 4 | issue= 22 | pages= 1-11 | pmid=14585162 | doi=10.1017/S1462399402005112 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14585162  }} </ref>
* It is mediated by the presence of [[androgens]], which is further reinforced by the fact that eunuchs do not bald.
* The molecular mechanism of action for the [[androgens]] such as [[testosterone]] and [[5α-dihydrotestosterone]] ([[DHT]]) to act on the hair follicle is not fully understood.
* It is theorized that some genes that regulate the follicle cycling may be regulated by the presence of androgens and that the expression of such genes are related to the concentrations of [[androgen]] and [[androgen receptor]]s in the follicle.<ref name="pmid14585162">{{cite journal| author=Ellis JA, Sinclair R, Harrap SB| title=Androgenetic alopecia: pathogenesis and potential for therapy. | journal=Expert Rev Mol Med | year= 2002 | volume= 4 | issue= 22 | pages= 1-11 | pmid=14585162 | doi=10.1017/S1462399402005112 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14585162  }} </ref>
* It is also theorized through observation of families with [[androgenetic alopecia]] that these genes related to the disease may act in an [[autosomal dominant]] manner in men and [[autosomal recessive]] manner in women, though there is strong evidence for a [[polygenic]] mode of inheritance.
* [[Finasteride]] is used to treat [[androgenetic alopecia]] being a potent [[5-alpha-reductase]] type-2 [[inhibitor]], inhibiting the conversion of [[testosterone]] to [[DHT]].


==== Template sentences ====
===Tinea capitis===
*The most important conditions/diseases associated with [disease name] include:
[[File:Tinea capitis47.jpg|200px|thumb|left|Tinea capitis - from atlasdermatologico.com.br]]
**Condition 1: A brief explanation of the condition and its association with the disease
* [[Tinea capitais]] is caused by [[dermatophyte]] species that are able to invade keratinized tissues like the hair.
**Condition 2: A brief explanation of the condition and its association with the disease
* It is usually transmitted via direct contact with organisms from other humans, animals, soil, or [[fomites]].
For an example of an associated conditions sub-section of pathophysiology, click [[Clubbing pathophysiology#Associated Conditions|here]].
* The [[dermatophyte]] infects the hair and grows towards the [[stratum corneum]]. It then affects the hair which becomes brittle and break.<ref name="pmid30725594">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725594 | doi= | pmc= | url= }} </ref>
* It may present with black dots, which is the non-inflammatory form of the disease, causing fracture of the hair. It also may present with intense inflammation which leads to follicular destruction, and may complicate with [[kerion]], an abscess in the [[scalp]], or [[favus]], another inflammatory form in which there is a honeycomb destruction of the hair shaft. Both are severe forms of the disease.<ref name="pmid30725594">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725594 | doi= | pmc= | url= }} </ref>
<br>
<br>
<br>


==Histopathology==
===Anagen Effluvium===
In androgenetic alopecia, there are miniaturized hair follicles with an increase in the telogen-to-anagen ratio without inflammatory reaction. In anagen effluvium, there is a decrease in anagen hair without any inflammatory response. Finally, in alopecia mucinosa, there is an infiltrate of the epidermis, dermis, and peribulbar lymphocytic infiltrate mainly anaplastic cells. In patients with alopecia areata, there is a peribulbar lymphocytic infiltrate with a decrease in the ratio of anagen to telogen hair. Telogen effluvium is characterized by an increase in the number of catagen hair. In tinea capitis, there is evidence of fungal infection as under a microscope along with a neutrophilic infiltrate.
* [[Anagen effluvium]] occurs mostly due to chemotherapy.
* Chemotherapeutic agents cause cessation of the hair growth during anagen phase, due to disruption of the cell cycle caused by the medication.<ref name="pmid30725594">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725594 | doi= | pmc= | url= }} </ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Needs content]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Dermatology]]

Latest revision as of 17:39, 24 December 2020

Alopecia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alopecia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Laser Therapy

Concealing Hair Loss

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alopecia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alopecia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alopecia pathophysiology

CDC on Alopecia pathophysiology

Alopecia pathophysiology in the news

Blogs on Alopecia pathophysiology

Directions to Hospitals Treating Alopecia

Risk calculators and risk factors for Alopecia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]

Overview

Since alopecia has many different causes, the pathophysiologic mechanism for its development varies widely according to the cause. Alopecia areata, for example, is related with CD8+ T-cell autoimmunity, while androgenetic alopecia is related with androgen hormones effects' on the hair follicle which leads to its miniaturization and hair loss. Tinea capitis on the other hand is an infectious disease that can damage the hair follicle and lead to definitive hair loss.

Pathophysiology

The most common causes for alopecia and its pathophysiology mechanism are briefly discussed below:

Alopecia Areata

Alopecia areata - from atlasdermatologico.com.br


Telogen effluvium

Traumatic alopecia

  • Usually seen on children that pull their hair, the same mechanism as traction alopecia.
  • May be associated with trichotillomania - a psychiatric condition in which the patient repeatedly pulls their hair.[7]

Androgenetic alopecia

Androgenetic alopecia - from atlasdermatologico.com.br
  • In androgenetic alopecia there is marked miniaturization of the hair follicle and disruption of the hair cycle.
  • It is thought that in androgenetic alopecia the hair loss is the result of the shortening of the anagen phases of hair development and enlongation of the telogen phase that gradually takes place until the hair eventually doesn't even leave the skin surface.[8]
  • The is also an increase in the period from the hair shedding to its regrowth.[8]
  • The miniaturization affects the hair follicle globally, including the dermal papilla which is essential for its maintenance.[8]
  • It is mediated by the presence of androgens, which is further reinforced by the fact that eunuchs do not bald.
  • The molecular mechanism of action for the androgens such as testosterone and 5α-dihydrotestosterone (DHT) to act on the hair follicle is not fully understood.
  • It is theorized that some genes that regulate the follicle cycling may be regulated by the presence of androgens and that the expression of such genes are related to the concentrations of androgen and androgen receptors in the follicle.[8]
  • It is also theorized through observation of families with androgenetic alopecia that these genes related to the disease may act in an autosomal dominant manner in men and autosomal recessive manner in women, though there is strong evidence for a polygenic mode of inheritance.
  • Finasteride is used to treat androgenetic alopecia being a potent 5-alpha-reductase type-2 inhibitor, inhibiting the conversion of testosterone to DHT.

Tinea capitis

Tinea capitis - from atlasdermatologico.com.br
  • Tinea capitais is caused by dermatophyte species that are able to invade keratinized tissues like the hair.
  • It is usually transmitted via direct contact with organisms from other humans, animals, soil, or fomites.
  • The dermatophyte infects the hair and grows towards the stratum corneum. It then affects the hair which becomes brittle and break.[9]
  • It may present with black dots, which is the non-inflammatory form of the disease, causing fracture of the hair. It also may present with intense inflammation which leads to follicular destruction, and may complicate with kerion, an abscess in the scalp, or favus, another inflammatory form in which there is a honeycomb destruction of the hair shaft. Both are severe forms of the disease.[9]




Anagen Effluvium

  • Anagen effluvium occurs mostly due to chemotherapy.
  • Chemotherapeutic agents cause cessation of the hair growth during anagen phase, due to disruption of the cell cycle caused by the medication.[9]

References

  1. Paus R, Ito N, Takigawa M, Ito T (2003). "The hair follicle and immune privilege". J Investig Dermatol Symp Proc. 8 (2): 188–94. doi:10.1046/j.1087-0024.2003.00807.x. PMID 14582671.
  2. Paus R, Bertolini M (2013). "The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives". J Investig Dermatol Symp Proc. 16 (1): S25–7. doi:10.1038/jidsymp.2013.7. PMID 24326544.
  3. Fischer J, Degenhardt F, Hofmann A, Redler S, Basmanav FB, Heilmann-Heimbach S; et al. (2017). "Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2". Exp Dermatol. 26 (6): 536–541. doi:10.1111/exd.13123. PMID 27306922.
  4. Trüeb RM, Dias MFRG (2018). "Alopecia Areata: a Comprehensive Review of Pathogenesis and Management". Clin Rev Allergy Immunol. 54 (1): 68–87. doi:10.1007/s12016-017-8620-9. PMID 28717940.
  5. Malkud S (2015). "Telogen Effluvium: A Review". J Clin Diagn Res. 9 (9): WE01–3. doi:10.7860/JCDR/2015/15219.6492. PMC 4606321. PMID 26500992.
  6. "StatPearls". 2020. PMID 28613598.
  7. "StatPearls". 2020. PMID 30844205.
  8. 8.0 8.1 8.2 8.3 Ellis JA, Sinclair R, Harrap SB (2002). "Androgenetic alopecia: pathogenesis and potential for therapy". Expert Rev Mol Med. 4 (22): 1–11. doi:10.1017/S1462399402005112. PMID 14585162.
  9. 9.0 9.1 9.2 "StatPearls". 2020. PMID 30725594.